Contact
searchSearch
HMP Global
Login

Metastatic Colorectal Cancer Education Center Resource Center

Metastatic Colorectal Cancer
Education Center

News
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
Anwaar Saeed, MD
Videos
Zanzalintinib Plus Atezolizumab Extends Survival in Metastatic Colorectal Cancer
11/05/2025
Anwaar Saeed, MD
Anwaar Saeed, MD, discusses results from the phase 3 STELLAR-303 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory metastatic colorectal cancer who are not MSI-high or mismatch repair...
Anwaar Saeed, MD, discusses results from the phase 3 STELLAR-303 trial evaluating zanzalintinib plus atezolizumab versus regorafenib in patients with chemorefractory metastatic colorectal cancer who are not MSI-high or mismatch repair...
Anwaar Saeed, MD, discusses...
11/05/2025
Oncology
Eric Christenson, MD
Videos
Nivolumab Plus Relatlimab For Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer
08/04/2025
Eric Christenson, MD
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses results from a phase 2 clinical trial highlighting the impact of combining nivolumab with relatlimab on the tumor microenvironment among previously treated patients with unresectable or metastatic mismatch...
Eric Christenson, MD, discusses...
08/04/2025
Oncology
Michael Overman, MD
Conference Coverage
Doublet vs Singlet Immunotherapy for Patients With Metastatic MSI-High Colorectal Cancer
05/24/2024
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, discussed advantages associated with treating patients with MSI-high colorectal cancer with doublet immunotherapy.
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Michael Overman, MD, discussed advantages associated with treating patients with MSI-high colorectal cancer with doublet immunotherapy.
At Great Debates and Updates in...
05/24/2024
Oncology
Carlotta Antoniotti, MD, PhD, University of Pisa
Videos
Atezolizumab With FOLFOXIRI Plus Bevacizumab for Metastatic Colorectal Cancer in the First-Line Setting
06/22/2023
Carlotta Antoniotti, MD, PhD
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting, Carlotta Antoniotti, MD, PhD, shares data from the AtezoTRIBE study evaluating the addition of atezolizumab to FOLFOXIRI plus bevacizumab for metastatic colorectal cancer.
At the 2023 ASCO annual meeting,...
06/22/2023
Oncology
Mohamed Salem, MD
Videos
Impact of Coexisting BRAF V600E Mutations on the Tumor Microenvironment in MSI-High or MMR-Deficient Colorectal Cancer
07/02/2022
Mohamed Salem, MD, discusses findings from a study exploring the impact of a BRAF V600E mutation on immunologic characteristics of the tumor microenvironment and associated genomic alterations in microsatellite instability (MSI)-high or...
Mohamed Salem, MD, discusses findings from a study exploring the impact of a BRAF V600E mutation on immunologic characteristics of the tumor microenvironment and associated genomic alterations in microsatellite instability (MSI)-high or...
Mohamed Salem, MD, discusses...
07/02/2022
Oncology
News
Atezolizumab Added to FOLFOXIRI and Bevacizumab Safe, Effective for Metastatic Colorectal Cancer
06/14/2022
Allison Casey
Findings from the phase 2 AtezoTRIBE trial show that the addition of atezolizumab to FOLFOXIRI and bevacizumab is safe and effective for patients with previously untreated metastatic colorectal cancer.
Findings from the phase 2 AtezoTRIBE trial show that the addition of atezolizumab to FOLFOXIRI and bevacizumab is safe and effective for patients with previously untreated metastatic colorectal cancer.
Findings from the phase 2...
06/14/2022
Oncology
News
Pembrolizumab Does Not Improve OS Over Chemotherapy in Patients With Colorectal Cancer: KEYNOTE-177
05/02/2022
John Otrompke, BA, JD
Superior OS for pembrolizumab over chemotherapy was not established among patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the phase 3 KEYNOTE-177 study.
Superior OS for pembrolizumab over chemotherapy was not established among patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the phase 3 KEYNOTE-177 study.
Superior OS for pembrolizumab...
05/02/2022
Oncology

Recent News

News
Atezolizumab Plus FOLFIRINOX and Bevacizumab Improves PFS Over Atezolizumab Alone for dMMR/MSI-H Metastatic Colorectal Cancer
01/12/2026
Emily Estrada
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial showed that combining atezolizumab with FOLFIRINOX and bevacizumab simproved progression-free survival compared to atezolizumab monotherapy for first-line treatment of dMMR/MSI-H metastatic colorectal cancer.
Results from the COMMIT trial...
01/12/2026
Oncology
News
Atezolizumab Added to FOLFOXIRI and Bevacizumab Safe, Effective for Metastatic Colorectal Cancer
06/14/2022
Allison Casey
Findings from the phase 2 AtezoTRIBE trial show that the addition of atezolizumab to FOLFOXIRI and bevacizumab is safe and effective for patients with previously untreated metastatic colorectal cancer.
Findings from the phase 2 AtezoTRIBE trial show that the addition of atezolizumab to FOLFOXIRI and bevacizumab is safe and effective for patients with previously untreated metastatic colorectal cancer.
Findings from the phase 2...
06/14/2022
Oncology
News
Pembrolizumab Does Not Improve OS Over Chemotherapy in Patients With Colorectal Cancer: KEYNOTE-177
05/02/2022
John Otrompke, BA, JD
Superior OS for pembrolizumab over chemotherapy was not established among patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the phase 3 KEYNOTE-177 study.
Superior OS for pembrolizumab over chemotherapy was not established among patients with previously untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the phase 3 KEYNOTE-177 study.
Superior OS for pembrolizumab...
05/02/2022
Oncology
News
Pembrolizumab Plus Lenvatinib Shows Promise in Recurrent Gynecologic Clear Cell Carcinomas
02/24/2026
Stephanie Holland
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA trial demonstrate promising antitumor activity and manageable safety with pembrolizumab plus lenvatinib in patients with recurrent clear cell carcinomas arising from the gynecological tract.
Results from the phase 2 LARA...
02/24/2026
Oncology
FDA Approval
FDA Approves Acalabrutinib Plus Venetoclax for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
02/20/2026
Emily Estrada
Based on results from the phase 3 AMPLIFY trial, the FDA has approved acalabrutinib plus venetoclax for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Based on results from the phase 3 AMPLIFY trial, the FDA has approved acalabrutinib plus venetoclax for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Based on results from the phase...
02/20/2026
Oncology
FDA Approval
FDA Approves Simplified Once-Monthly Amivantamab Plus Hyaluronidase Regimen for First-Line EGFR-Mutated Advanced NSCLC
02/18/2026
Stephanie Holland
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new, simplified once-monthly dosing schedule for amivantamab plus hyaluronidase when administered in combination with lazertinib for the first-line treatment of EGFR-mutated advanced non-small cell lung cancer.
The FDA has approved a new,...
02/18/2026
Oncology
FDA Alerts
FDA Grants Breakthrough Therapy Designation to Subcutaneous Amivantamab in HPV-Unrelated Head and Neck Squamous Cell Carcinoma
02/18/2026
Stephanie Holland
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase 1b/2 OrigAMI-4 study, the FDA has granted breakthrough therapy designation to amivantamab plus hyaluronidase for patients with HPV-unrelated recurrent or metastatic head and neck squamous cell carcinoma.
Based on data from the phase...
02/18/2026
Oncology
Kelly E. McCann, MD, PhD
News
OLN Great Debates: Navigating Evolving Evidence and Treatment Decisions in Breast Oncology
02/17/2026
Kelly McCann, MD, PhD
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast cancer, staying current has never been more challenging. New trial data, biomarker-driven strategies, and therapeutic options continue to emerge at a rapid pace, yet translating that evidence into confident,...
For clinicians treating breast...
02/17/2026
Oncology
News
Pirtobrutinib Demonstrates Promise in Relapsed or Refractory Marginal Zone Lymphoma
02/17/2026
Stephanie Holland
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN study demonstrated that pirtobrutinib showed promising efficacy and tolerable safety in heavily pretreated patients with relapsed or refractory marginal zone lymphoma.
Results from the phase 1/2 BRUIN...
02/17/2026
Oncology
News
Nivolumab Plus Chemotherapy Maintains Survival Advantage in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from the phase 3 CheckMate 649 trial demonstrate that adding nivolumab to chemotherapy continues to prolong survival in previously untreated patients with non-HER2-positive, unresectable or metastatic...
Long-term follow-up results from...
02/12/2026
Oncology
News
Iopofosine I 131 Shows Durable Responses in Heavily Pretreated Waldenström Macroglobulinemia
02/12/2026
Emily Estrada
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug conjugate iopofosine I 131 demonstrated high and durable response rates among patients with pretreated Waldenström macroglobulinemia, with a manageable hematologic safety profile.
Novel phospholipid drug...
02/12/2026
Radiopharmaceutical Education Institute
News
Maintenance Palbociclib Extends PFS in HR-Positive, HER2-Positive Metastatic Breast Cancer
02/11/2026
Stephanie Holland
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA trial demonstrated that the adding palbociclib to maintenance anti-HER2 and endocrine therapy significantly improved progression-free survival in HR-positive, HER2-positive metastatic breast cancer.
Results from the phase 3 PATINA...
02/11/2026
Oncology
News
First-Line Toripalimab Improves PFS in Advanced Melanoma Predominantly of Acral Subtype
02/11/2026
Stephanie Holland
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3 MELATORCH trial demonstrated that first-line toripalimab significantly improved progression-free survival in patients with advanced melanoma, including those with predominantly acral subtype disease.
Results from the phase 3...
02/11/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use